English
Anti-Mouse CD27 In Vivo Antibody - Low Endotoxin (RM27-3E5)
Anti-Mouse CD27 In Vivo Antibody - Low Endotoxin (RM27-3E5), Host: Rat, Rat IgG1 kappa
Artikelnummer
ICH1185-50MG
Verpackungseinheit
50mg
Hersteller
Ichorbio
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Target: CD27.
Clone: RM27-3E5.
Specificity: RM27-3E5 activity is directed against mouse CD27.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution: CD27 is expressed on T cells, B cells, and NK cells.
Background: CD27 is a glycosylated, type I transmembrane protein of the TNFR superfamily that is constitutively expressed on the surface of progenitor and naïve T cells as well as subsets of natural killer (NK) and B cells. CD27 is an immune-checkpoint receptor and ligation with CD70 results in co-stimulatory effects that enhance primary, memory, and recall T cell responses. CD27 signaling has been targeted for the development of viral, autoimmune, and anti-tumor immunotherapies.RM27-3E5 (rat IgG2a) was raised against recombinant mouse CD27-human IgG1 Fc fusion protein and purified from ascites using protein G columns. RM27-3E5 enhances anti-CD3-stimulated T cell proliferation when immobilized in vitro and augments ovalbumin-specific cytotoxic T lymphocyte (CTL) induction when administered in vivo.RM27-3E5 is an agonistic antibody and has been found to support the control of both established lung metastases and subcutaneous tumors. An anti-tumor effect was also observed with RM27-3E5 against EG7/CD27(+) and EG7/CD27(−) tumors, with the effect mediated mainly by T cells with a minor contribution by NK cells. RM27-3E5 exerts its potent anti-tumor effect by inducing a tumor-specific CTL response. RM27-3E5 has potential utility as a non-depleting agonistic anti-CD27 mAb to enhance anti-tumor immunity.
Immunogen: Mouse CD27-human IgG1 Fc fusion protein.
Concentration: ≥ 5.0 mg/ml.
Formulation: This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Purity: ≥95% monomer by analytical SEC, >95% by SDS Page.
Endotoxin: <1.0 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 5%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Clone: RM27-3E5.
Specificity: RM27-3E5 activity is directed against mouse CD27.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution: CD27 is expressed on T cells, B cells, and NK cells.
Background: CD27 is a glycosylated, type I transmembrane protein of the TNFR superfamily that is constitutively expressed on the surface of progenitor and naïve T cells as well as subsets of natural killer (NK) and B cells. CD27 is an immune-checkpoint receptor and ligation with CD70 results in co-stimulatory effects that enhance primary, memory, and recall T cell responses. CD27 signaling has been targeted for the development of viral, autoimmune, and anti-tumor immunotherapies.RM27-3E5 (rat IgG2a) was raised against recombinant mouse CD27-human IgG1 Fc fusion protein and purified from ascites using protein G columns. RM27-3E5 enhances anti-CD3-stimulated T cell proliferation when immobilized in vitro and augments ovalbumin-specific cytotoxic T lymphocyte (CTL) induction when administered in vivo.RM27-3E5 is an agonistic antibody and has been found to support the control of both established lung metastases and subcutaneous tumors. An anti-tumor effect was also observed with RM27-3E5 against EG7/CD27(+) and EG7/CD27(−) tumors, with the effect mediated mainly by T cells with a minor contribution by NK cells. RM27-3E5 exerts its potent anti-tumor effect by inducing a tumor-specific CTL response. RM27-3E5 has potential utility as a non-depleting agonistic anti-CD27 mAb to enhance anti-tumor immunity.
Immunogen: Mouse CD27-human IgG1 Fc fusion protein.
Concentration: ≥ 5.0 mg/ml.
Formulation: This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Purity: ≥95% monomer by analytical SEC, >95% by SDS Page.
Endotoxin: <1.0 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 5%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
| Artikelnummer | ICH1185-50MG |
|---|---|
| Hersteller | Ichorbio |
| Hersteller Artikelnummer | ICH1185-50MG |
| Green Labware | Nein |
| Verpackungseinheit | 50mg |
| Mengeneinheit | STK |
| Reaktivität | Mouse (Murine) |
| Klonalität | Monoclonal |
| Methode | Immunoprecipitation, Flow Cytometry, Functional Assay |
| Isotyp | Rat IgG1 kappa |
| Wirt | Rat |
| Produktinformation (PDF) | Download |
| MSDS (PDF) | Download |
Verwandte Artikel
Markieren Sie die Artikel, um Sie dem Warenkorb hinzuzufügen oder
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
